# Clarity Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/clarity-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Sydney, Australia
- Website: www.claritypharmaceuticals.com
- Total disclosed funding: $2.6M
- Latest round: Seed (May 1, 2014)
- Investors on record: 6

## About

Clarity Pharmaceuticals is a biopharmaceutical company specializing in the development of advanced radiopharmaceuticals for targeted cancer therapies and diagnostics, enhancing treatment options in oncology.Founded in 2010 in Sydney, Australia, Clarity Pharmaceuticals develops innovative radiopharmaceutical products. The company raised AUD 92 million in an IPO on August 23, 2021, marking a significant financing milestone. The founder, Tony Romagnino, has a history in the biopharmaceutical sector, contributing to the company’s strategic direction under CEO Colin Biggin.Clarity Pharmaceuticals specializes in developing advanced radiopharmaceutical products that leverage its proprietary SAR Technology platform. Its primary offerings include SAR-bisPSMA, SAR-Bombesin, and SARTATE, each designed to deliver targeted therapy and diagnostic capabilities for various cancers. SAR-bisPSMA targets prostate cancer as both a diagnostic and treatment option, SAR-Bombesin serves as a pan-cancer theranostic applicable to multiple cancer types, and SARTATE targets neuroblastoma and neuroendocrine tumors, addressing significant unmet clinical needs. These products are utilized by healthcare providers in oncology departments across North America, Europe, and Asia-Pacific, aiming to enhance patient outcomes.Clarity Pharmaceuticals generates revenue through partnerships and collaborations with healthcare institutions and research organizations in oncology. The revenue model is centered on the clinical development and commercialization of its flagship products, which are sold directly to hospitals and clinics. Revenue streams include upfront payments upon entering partnership agreements and milestone payments tied to clinical trial progress and regulatory approvals. Once launched, sales may occur through B2B transactions with established distribution channels in the oncology market. The company’s focus on scalable and cost-effective solutions positions it to capture substantial market share in the growing field of radiopharmaceuticals.Clarity Pharmaceuticals plans to leverage the AUD 92 million raised in its IPO to support the development of new products and expand its market presence. The company is focused on designing and launching additional radiopharmaceuticals to address various cancers, with specific timelines for product launches to be announced. Furthermore, Clarity aims to enter new markets in Europe and Asia-Pacific by 2024, enhancing its global footprint. The recent funding will be critical in advancing clinical trials and regulatory processes for upcoming products.

## Funding rounds

- Seed, May 1, 2014, $1M — Sydney Angels
- Seed, Dec 5, 2012, $1.6M — 500 Global, Baseline Ventures, Freestyle VC, Real Ventures, Version One Ventures

## Investors

- 500 Global (https://capitalatlas.ai/funds/500-global) — Seed
- Baseline Ventures (https://capitalatlas.ai/funds/baseline-ventures) — Seed
- Freestyle VC (https://capitalatlas.ai/funds/freestyle-vc) — Seed
- Real Ventures — Seed
- Version One Ventures (https://capitalatlas.ai/funds/version-one-ventures) — Seed
- Sydney Angels (https://capitalatlas.ai/funds/sydney-angels) — Seed